Wockhardt sets timeline for resolving FDA bans; Sun profit suffers on Ranbaxy fold-in;

@FiercePharma: Tech makers market health wearables to dog owners. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro. Article | Follow @CarlyHFierce

> Wockhardt hopes to resolve the FDA ban on two of its plants by the end of its current fiscal year. More

> Sun Pharma's profits for the three months ended March 31 missed analysts estimates thanks to the cost of integrating new buy Ranbaxy Laboratories. Report

> A jury has ordered Abbott Laboratories ($ABT) to pay $23 million in punitive damages to a Minnesota girl whose family blamed the company's epilepsy drug Depakote for causing her birth defects. More

> The FDA has approved Pfizer's ($PFE) Rapamune to treat a rare lung disease. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Deerfield backs startup with $10M for its hemodialysis vascular access implant. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ info from the company: CareFusion's Avea ventilator recalled as potentially deadly. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific slapped with $100M verdict in vaginal mesh suit. News | Follow @EmilyWFierce

> Zimmer to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close. More

> Nonprofit leads $17.5M round for medical image exchange startup LifeImage. Article

Biotech News

@FierceBiotech: Buzz: Cellectis could be in a line for a $1.6B Pfizer buyout. Article | Follow @FierceBiotech

@JohnCFierce: Is this a good time to tout my survey (with Bloomberg Intelligence)? Are biotech assets overvalued? Check it out | Follow @JohnCFierce

> Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie. More

> Heron soars as twice-rejected nausea drug comes through in Phase III. Report

And Finally... HIV treatment with antiretroviral drugs should begin immediately following diagnosis, U.S. health officials say. More (sub. req.)

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.